Stocklytics Platform
Asset logo for symbol IDYA
Ideaya Biosciences
IDYA53
$31.28arrow_drop_up4.26%$1.28
Asset logo for symbol IDYA
IDYA53

$31.28

arrow_drop_up4.26%
no data available for key stats

There's no data available for key stats

no data available for ratios/profitability stats

There's no data available for ratios/profitability stats

Fundamentals
RPS-
Gross Profit-
EBITDA-
Total Debt-
P/S Ratio-
Enterprise to EBITDA-
Profit Margin-
ROA-
Debt/Equity Ratio-
Payout Ratio-
Industry average yield-
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Stock Performance

IDYA-
US Tech-
US Market-

Ideaya Biosciences (IDYA) Statistics

Ideaya Biosciences Inc (IDYA) is a leading biotechnology company that specializes in the development of precision medicine for oncology indications. The company is focused on leveraging its expertise in synthetic lethality, immuno-oncology, and precision oncology to develop targeted therapies for patients with genetically-defined cancers. With a mission to transform cancer care, Ideaya Biosciences is dedicated to developing innovative therapies that can improve patient outcomes and address unmet medical needs.
When it comes to IDYA stock statistics, investors can find a range of valuable information. This includes the stock's current price, market capitalization, trading volume, and daily price fluctuations. These statistics can provide insights into the overall performance and market sentiment surrounding Ideaya Biosciences. Additionally, investors may also want to consider other valuation metrics such as price-to-earnings ratios, price-to-sales ratios, and price-to-book ratios to gain a deeper understanding of the stock's valuation compared to its peers.
add Ideaya Biosciences  to watchlist

Keep an eye on Ideaya Biosciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Ideaya Biosciences (IDYA) stock's performance compared to its sector and the market over the past year?

Over the past year, Ideaya Biosciences (IDYA) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 35.41%, Ideaya Biosciences has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 76.95%, it has fallen short of the market average. This comparison highlights Ideaya Biosciences 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Ideaya Biosciences (IDYA) stock?

The PE ratio for Ideaya Biosciences (IDYA) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Ideaya Biosciences (IDYA) stock?

The Earnings Per Share (EPS) for Ideaya Biosciences (IDYA), calculated on a diluted basis, is -$2.3. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Ideaya Biosciences (IDYA) stock?

The operating margin for Ideaya Biosciences (IDYA) is -5.73K%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Ideaya Biosciences (IDYA) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Ideaya Biosciences (IDYA) is -$222.31M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Ideaya Biosciences (IDYA) have?

Ideaya Biosciences (IDYA) has a total debt of $18.8M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$381.49M.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level